J. Biol. Chem., Vol. 261, Issue 19, 8817-8823, 07, 1986
Effects of beta-adrenergic stimulation on 1-O-hexadecyl-2-acetyl-sn- glycero-3-phosphocholine-mediated vasoconstriction and glycogenolysis in the perfused rat liver
RA Fisher, R Kumar, DJ Hanahan and MS Olson
The beta-adrenergic agonist isoproterenol inhibited the glycogenolytic
response of platelet-activating factor (AGEPC, 1-O-hexadecyl-2-acetyl-
sn-glycero-3-phosphocholine) in perfused livers derived from fed rats.
AGEPC-stimulated hepatic vasoconstriction, measured by increases in portal
vein pressure, also was inhibited by prior isoproterenol infusion.
Isoproterenol-mediated inhibition of these hepatic responses to AGEPC was
not apparent when isoproterenol (10 microM) was coinfused with the
beta-receptor antagonist propranolol (75 microM) or when isoproterenol was
replaced with the alpha-adrenergic agonist phenylephrine (10 microM).
alpha-Agonist-induced glycogenolysis and vasoconstriction in the perfused
liver was unaffected by isoproterenol infusion. Glucagon (2.3 nM) had no
effect on the glycogenolytic or vasoconstrictive responses of the liver to
AGEPC despite the fact that glucagon increased hepatic cAMP levels to a far
greater extent than isoproterenol. Additionally, inhibition of the hepatic
responses to AGEPC by isoproterenol occurred in perfused livers from mature
rats (i.e. greater than 300 g) in which liver parenchymal cells lack
functional beta-adrenergic receptors. The data presented in this study
illustrate a specific inhibition of AGEPC-induced hepatic glycogenolysis
and vasoconstriction by beta-adrenergic stimulation of the perfused liver.
This inhibition appears to be mediated by interaction of isoproterenol with
nonparenchymal cells within the liver. These findings are consistent with
the concept that AGEPC stimulates hepatic glycogenolysis by an indirect
mechanism involving hepatic vasoconstriction.